small molecule

TRETINOIN

TRETINOIN

Loss of exclusivity—loss of exclusivity
CompanyAmneal Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameTRETINOIN
Active ingredientTRETINOIN
Strength0.08%
Dosage formGEL
RouteTOPICAL
ModalitySmall molecule
FDA approvalMay 2026
Marketing statusRX

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.